The glucagon-like peptide 1 (GLP-1) agonist tirzepatide lowers the risk for cardiovascular (CV) events in patients with obesity and heart failure with preserved ejection fraction (HFpEF), whether they have general adiposity, measured with the body mass index (BMI), or central adiposity, measured with the waist-to-height ratio…
Leave a Comment Leave a Comment
